Compare ACRS & VREX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACRS | VREX |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 868.5M | 783.5M |
| IPO Year | 2015 | 2016 |
| Metric | ACRS | VREX |
|---|---|---|
| Price | $3.90 | $18.46 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 3 |
| Target Price | $10.18 | ★ $18.90 |
| AVG Volume (30 Days) | ★ 3.6M | 526.1K |
| Earning Date | 11-05-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.01 | N/A |
| EPS | N/A | ★ 0.23 |
| Revenue | $1,683,000.00 | ★ $811,000,000.00 |
| Revenue This Year | N/A | $2.52 |
| Revenue Next Year | N/A | $3.97 |
| P/E Ratio | ★ N/A | $80.30 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.74 | $9.09 |
| 52 Week High | $6.60 | $18.63 |
| Indicator | ACRS | VREX |
|---|---|---|
| Relative Strength Index (RSI) | 33.30 | 71.61 |
| Support Level | $3.16 | $12.00 |
| Resistance Level | $4.63 | $18.63 |
| Average True Range (ATR) | 0.41 | 0.04 |
| MACD | -0.15 | -0.10 |
| Stochastic Oscillator | 28.38 | 38.89 |
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Varex Imaging Corp Designs, manufactures, sells, and services X-ray imaging components, including X-ray tubes, detectors, ionization chambers, high-voltage connectors, software, collimators, generators, exposure control devices, and heat exchangers.. The company operates through two segments: Medical, the key revenue driver, providing X-ray imaging components and accessories for healthcare applications, and Industrial, which provides Linatron X-ray accelerators, X-ray tubes, flat panel detectors, high-voltage connectors, and coolers for non-medical use. Geographically, it generates the majority of its revenue from Europe, the Middle East, and Africa (EMEA), with the rest coming from the Americas and Asia Pacific.